6,277 reports of this reaction
2.5% of all ATENOLOL reports
#5 most reported adverse reaction
DYSPNOEA is the #5 most commonly reported adverse reaction for ATENOLOL, manufactured by Almatica Pharma LLC. There are 6,277 FDA adverse event reports linking ATENOLOL to DYSPNOEA. This represents approximately 2.5% of all 252,348 adverse event reports for this drug.
Patients taking ATENOLOL who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is a less commonly reported adverse event for ATENOLOL, but still significant enough to appear in the safety profile.
In addition to dyspnoea, the following adverse reactions have been reported for ATENOLOL:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 6,277 FDA reports for ATENOLOL. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 2.5% of all adverse event reports for ATENOLOL, making it a notable side effect.
If you experience dyspnoea while taking ATENOLOL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.